4th Midwest Cellular Conference: Treatment Options For Advanced Hematological Malignancies
In-Person Event
Apr 25 - 26, 2026
Chicago, Illinois, USA
6.75 AMA PRA Category 1 Credits™ ...OVERVIEW
4th Midwest Cellular Conference: Treatment Options For Advanced Hematological Malignancies is organized by Meeting Achievements, LLC, Rush University Medical Center and will be held from Apr 25 - 26, 2026 at Hyatt Regency Chicago, Chicago, Illinois, United States of America.
Program Overview:
Treatment options for relapsed/refractory (advanced) hematologic malignancies have progressed rapidly in only the last decade. Development of revolutionary treatment options, including CAR T-cell therapy, novel immunotherapies, and novel chemotherapeutic agents has only accelerated since the first product targeting CD19 was developed in 2003. These developments provide excellent opportunities for patients, and with opportunities arrive challenges for clinicians in maintaining optimal approaches to care. To address the educational need the 4th Midwest Therapy Cellular Conference: Treatment Options for Advanced Hematologic Malignancies is planned .
Learning Objectives:
Following participation in this activity, learners will:
- Discuss individualized treatment options for high-risk patients with plasma cell diseases (multiple myeloma (MM), amyloidosis), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL),non-Hodgkin Lymphoma (NHL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA).
- Include autologous or allogeneic HCT and/or CAR-T cell therapy in treatment plans for patients with various refractory (advanced) hematologic malignancies.
- Manage potential complications resulting from autologous or allogeneic HCT and/or CAR-T cell therapy.
- Utilize newer chemotherapeutic treatment options in conjunction with HCT and CAR-T cell therapy for patients with various refractory (advanced) hematologic malignancies.
KEY DATES
25 Apr, 2026
Event Start Date
26 Apr, 2026
Event End Date
ACCREDITATION & CREDITS
Accreditation & Credit Designation:
Accreditation Statement:
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements:
For Physicians:
Rush University Medical Center designates this Live Activity for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
For Nursing:
Rush University Medical Center designates this live activity for a maximum of 6.75 nursing contact hour(s).
For Pharmacy:
Rush University Medical Center designates this knowledge-based live activity for a maximum of 6.75 contact hour(s) for pharmacists.
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
TARGET AUDIENCE
PhysicianNursingPharmacistOncologistsResidentsNursesHematologistFellowsOther Health ProfessionalsMedical OncologistsOncological Nursing StaffAdvanced Practice ProvidersSPECIALITIES
HematologySUGGESTED HOTELS
CONFERENCE VENUE
Hyatt Regency ChicagoRELATED CONFERENCES & LIVE WEBINARS
Quick Links